Cart
sales@molnova.com
Hypertrehalosaemic Neuropeptide, Heliothis zea
CAS No. 117107-54-7
Hypertrehalosaemic Neuropeptide, Heliothis zea( ——— )
Catalog No. M41454 CAS No. 117107-54-7
Hypertrehalosaemic Neuropeptide, Heliothis zea
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 25MG | Get Quote | Get Quote |
|
| 50MG | Get Quote | Get Quote |
|
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameHypertrehalosaemic Neuropeptide, Heliothis zea
-
NoteResearch use only, not for human use.
-
Brief DescriptionHypertrehalosaemic Neuropeptide, Heliothis zea
-
DescriptionHypertrehalosaemic Neuropeptide, Heliothis zea
-
In Vitro———
-
In Vivo———
-
Synonyms———
-
PathwayOthers
-
TargetOther Targets
-
Recptor———
-
Research Area———
-
Indication———
Chemical Information
-
CAS Number117107-54-7
-
Formula Weight1078.17
-
Molecular FormulaC49H67N13O15
-
Purity>98% (HPLC)
-
Solubility———
-
SMILES———
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
PF-04937319
PF-04937319 is an activator of glucokinase (EC50 =154.4 ?μM). PF-04937319 maintains glucose-lowering efficacy while mitigating the risk of hypoglycemia observed with many other glucokinase activators. PF-04937319 can be used in research on the treatment of type 2 diabetes mellitus.
-
RET-IN-1
RET-IN-1 is a RET kinase inhibitor extracted from patent WO2018071447A1, Compound Example 552.
-
PF-05231023
PF-05231023 is a long-acting fibroblast growth factor 21 (FGF21) analog and is an FGF21-receptor agonist. It is also suitable for development as a potential treatment for T2DM. PF-05231023 is a analog of long-acting fibroblast growth factor 21.
